Roche Glycart Ag

Hoffmann-la Roche Inc.

Engmab Sarl

Bristol-myers Squibb Compnay

Engmab Ag

F. Hoffmann-la Roche Ag

Engmab Beta Holdings LLC

Oliver Ast

Christian Klein

Pablo Umana

Ekkehard Moessner

Ralf Hosse

Anne Freimoser-Grundschober

Marina Bacac

Peter Bruenker

Thomas U Hofer

Wolfgang Schaefer

Joerg Thomas Regula

Pablo Umaña

Michael Molhoj

Stefan Klostermann

Klaus Strein

Samuel Moser

Minh Diem Vu

Tanja Fauti

Sabine Imhof-Jung

Sylvia Herter

Valeria G Nicolini

Christiane Neumann

Lydia Jasmin Hanisch

Ramona Murr

Sabine Jung-Imhof

Tina Weinzierl

Christiane Jaeger

Lydia Jasmin Duerner

Camille Delon

Valerla G Nicolini

Anne Freimoser-grundschober

The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.

Bispecific antibodies against CD3EPSILON and ROR1

The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.

Immunoconjugates

The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Bispecific T cell activating antigen binding molecules

The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the &#x3b1;-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.

Mutant interleukin-2 polypeptides

An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-&#x3ba;B activation, BAFF-dependent NF-&#x3ba;B activation, and does not alter NF-&#x3ba;B activation without BAFF and APRIL is useful as a therapeutic agent.

Method for the selection of antibodies against BCMA

The invention relates to new antibodies against BCMA, their manufacture and use.

Monoclonal antibodies against BCMA

A bispecific bi- or trivalent antibody specifically binding to the two targets which are extracellular domain of human B cell maturation antigen (BCMA) and human CD3&#x3b5;, wherein the variable domains VL and VH in a light chain and the respective heavy chain are replaced by each other, characterized in comprising a constant domain CL wherein the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the respective constant domain CH1 the amino acid at position 147 and the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to EU index of Kabat). Also the manufacture and use of said antibody.

Bispecific antibodies against CD3&#x3f5; and BCMA

A bispecific antibody specifically binding to the two targets human CD3&#x3b5; and human BCMA, wherein the variable domains of one antibody portion are replaced by each other, and characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-&#x3ba;B activation, BAFF-dependent NF-&#x3ba;B activation, and does not alter NF-&#x3ba;B activation without BAFF and APRIL is useful as a therapeutic agent.

Bispecific antibodies against CD3 and BCMA

Growing community of inventors

Bassersdorf, Switzerland

Oliver Ast